15 results about "Accessory Olfactory Bulb" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention provides a nomeline nasal-brain delivery preparation for transnasal region mucosa administration, and an auxiliary material mixture of the nasal-brain delivery preparation comprises 1) phospholipid, and 2) any one of diluent ethyl oleate, isopropyl myristate, sesame oil or castor oil; optionally, the auxiliary material mixture can also comprise 3) a dissolving agent such as ethanol or diethylene glycol monoethyl ether, the auxiliary material mixture is a non-aqueous system, and a solution prepared from the mixture of the two or three auxiliary materials can be absorbed by the nasal meatus olfactory mucosa after being administrated through the nasal region mucosa, can be quickly conducted to the brain olfactory bulb region along olfactory nerves and cerebrospinal fluid, and can be used for treating the brain olfactory bulb. The problems that the peripheral side effect is high due to poor brain targeting of the medicine, the medicine takes effect slowly and the like are solved.

The invention belongs to the technical field of computer vision, and discloses a zero-sample anti-interference target detection method and a related device, and the method comprises the steps: obtaining a to-be-detected image; inputting the to-be-detected image into the target detection model, and outputting a target detection result of the to-be-detected image; wherein the target detection model is constructed based on the architecture of an improved convolutional neural network, and the improved convolutional neural network is a standard convolutional neural network integrated with a bionic framework BioNet; the bionic framework BioNet comprises a visual focusing simulation module and an olfactory bulb simulation module; according to the invention, the bionic framework BioNet is integrated to the standard convolutional neural network to construct the target detection model, the dependence on interference type prior knowledge is eliminated from the bottom layer of the model, the noise type does not need to be preset, the detection network is endowed with internal robustness from the model architecture level, the hardware resource consumption of model training and the system operation complexity are effectively reduced, and the detection efficiency is improved. And extra calculation overhead is reduced.

This invention discloses an olfactory electrostimulation model for automatically generating current stimulation signals for an artificial nose, relating to the technical field of olfactory stimulation signal generation using biomimetic neural networks. The implementation steps include: First, constructing a biomimetic neural network framework. Based on the neuronal anatomical structure of the olfactory epithelium and olfactory bulb system, extracting the main neuron types, and organizing them according to their connection methods in biological systems; Second, using the Hindmarsh-Rose neuron model to model various neurons in the constructed network and simulate their dynamic firing behavior; Subsequently, setting the connection weights between neurons and the interlayer transmission current to realize the computational model of the entire biomimetic neural network; Finally, in the odor encoding and stimulation signal generation stage, the odor detection curve of the electronic nose is used as an external stimulus input to the biomimetic neural network. The network calculates and generates a series of peak signals, which are output as current stimulation signals to the olfactory bulb for stimulation, thereby realizing the olfactory induction function of the artificial nose.

The invention discloses a lipophilic modified nucleic acid medicine composition and application thereof, the lipophilic modification is saturated or unsaturated C4-C30 alkyl, the composition comprises an absorption enhancer, and the method is that the lipophilic modified nucleic acid medicine is delivered to the brain through the nasal mucosa. Nucleic acid drugs are transmitted into the olfactory bulb region through a neural pathway, namely, cross-olfactory mucosa, bypass BBB and directly enter the brain, the drug concentration content of the olfactory bulb is far higher than that of other tissues of the brain, and the tissues except the olfactory bulb are uniformly distributed, so that the olfactory bulb can be used as a drug reservoir and gradually and slowly spread to the other tissues of the brain; the long-time drug effect can be maintained by one-time drug administration, so that the drug administration frequency can be reduced. Compared with intrathecal injection, by adopting the composition disclosed by the invention for nasal administration and using 1 / 2 of intrathecal administration dosage, the same intrathecal steady-state distribution as intrathecal distribution can be achieved, so that the method disclosed by the invention is safer, noninvasive and efficient.

The invention relates to a multi-mode eye-brain collaborative maintenance intelligent device, and belongs to the technical field of eye-brain nursing equipment.The device is provided with an impression stimulation module, the impression stimulation module stimulates mild energy of an impression acupoint, the mild energy can be directly conducted to a paranasal sinus olfactory bulb in the deep part of a nasal cavity, the area is the starting end of paranasal sinus nerves, the paranasal sinus nerves are branches of cranial nerves, and therefore the paranasal sinus acupoint can be stimulated; the neural pathway directly extends to brain hippocampus, brain marginal tissue, pituitary gland and other core structures related to neuronutrition and brain metabolism; after stimulation, the paranasal sinus olfactory bulb and paranasal sinus nerves are activated to form a neural pathway for targeted delivery of the atomized liquid, so that the atomized particles of the brain care liquid are adsorbed on the surface of the paranasal sinus olfactory bulb and permeate into the brain along the activated neural pathway, and meanwhile, the permeability of the blood brain barrier is improved, so that the delivery resistance of the atomized liquid to related functional areas of the brain is further reduced, and the targeted delivery of the atomized liquid is realized. Precise nutrition for cranial nerves is achieved, and the problem that brain maintenance is invalid due to the fact that conventional nasal cavity atomized liquid enters the lung is thoroughly solved.

The utility model relates to the technical field of fixing devices, in particular to an integrated fixing device for manufacturing rodent pathological sections, which comprises a fixing device shell and a fixing device cover plate which are rotatably connected. The fixing device comprises a fixing device shell, a plurality of brain cutting clamping grooves are formed in the periphery of the fixing device shell, brain clamping grooves are formed in the bottom of the fixing device shell, the brain clamping grooves comprise a cerebellum fixing groove, a brain fixing groove and an olfactory bulb fixing groove, and the cerebellum fixing groove, the brain fixing groove and the olfactory bulb fixing groove are integrated. The closed fixing groove can be adopted, formalin volatilization is reduced, the brain tissue fixing function and the material taking function are integrated, and the operation process is simplified.

This invention discloses a nasal delivery system for PF4 mRNA, comprising mesenchymal stem cell exosomes encapsulating PF4 mRNA and pharmaceutically acceptable excipients, wherein the nucleotide sequence of the PF4 mRNA is shown in SEQ NO:1. This invention utilizes MSC-Exo to deliver PF4 mRNA via nasal administration. Thus, the MSC-Exo encapsulating PF4 mRNA can bypass the BBB and efficiently enter the brain through the olfactory bulb. Furthermore, PF4 mRNA and MSC-Exo can exert a synergistic effect, significantly reducing Aβ-induced inflammatory responses and improving cognitive function in AD mice. The nasal delivery system for PF4 mRNA provided by this invention can be used to prepare drugs for treating neurodegenerative diseases, preferably, for preparing drugs for treating Alzheimer's disease.

The invention discloses a nasal delivery double-chain RNA / Mn < 2 + > nano-drug as well as a preparation method and application thereof in immunotherapy. And adding the polymer into a solution containing double-stranded RNA and manganese salt, and self-assembling to form the nasal delivery double-stranded RNA / Mn < 2 + > nano-drug. The invention provides a new technical scheme for the barrier of the BBB. The nano delivery system has the advantages in the aspects of overcoming the BBB and improving the in-vivo biological distribution of the drug, and the surface of the nano carrier is modified with a ligand targeted to an endothelial cell overexpression receptor, such as ApoE peptide and the like, so that the drug can be delivered to penetrate through the BBB; a non-invasive nasal-brain delivery strategy becomes a new scheme for improving drug availability and reducing toxic and side effects, the drug can bypass BBB and rapidly enter brain parenchyma through olfactory bulb and trigeminal nerve conduction pathways, and an immune drug delivered by the nasal cavity can rapidly enter nasopharynx-related lymphatic tissue (NALT) and is transferred to CLN through a lymphatic network around the nasal cavity, so that the immune drug can be rapidly delivered to the nasopharynx-related lymphatic tissue (NALT). Further, a potent local immune response aiming at the in-situ GBM is induced.

The present disclosure provides a wearable device for measuring an olfactory bulb potential signal by applying olfactory bulb electrical stimulation. The wearable device comprises: a front unit including a plurality of electrode interfaces having holes formed therethrough in the front-to-rear direction; a plurality of first angle adjustment knobs that adjust the angle of the front unit; a plurality of connection units that connect the ends of the front unit to the plurality of first angle adjustment knobs; a plurality of electrodes coupled to the holes formed in the plurality of electrode interfaces and in contact with a user's head; and a control unit that applies an electrical signal to the user through the plurality of electrodes and measures an olfactory bulb potential signal of the user through the plurality of electrodes.

A method and an apparatus for diagnosing dementia of a patient on the basis of an olfactory bulb electrical signal are disclosed. A method according to one embodiment of the present disclosure comprises the steps of: acquiring a feature map corresponding to an electrical signal for an olfactory bulb of a patient; extracting feature information corresponding to an element corresponding to a normal patient on the basis of the acquired feature map; and diagnosing dementia of the patient on the basis of the extracted feature information.

The invention discloses a nasal delivery PF4 mRNA delivery system, the nasal delivery PF4 mRNA delivery system comprises a mesenchymal stem cell exosome encapsulated with PF4 mRNA and a pharmaceutically acceptable auxiliary material, and the nucleotide sequence of the PF4 mRNA is as shown in SEQ NO: 1. According to the invention, the MSC-Exo is utilized to deliver the PF4 mRNA, and the administration is carried out in a nasal administration manner, so that the MSC-Exo encapsulated with the PF4 mRNA can bypass BBB to efficiently enter the brain through olfactory bulbs, and the PF4 mRNA and the MSC-Exo can play a synergistic effect, so that the inflammatory reaction induced by A beta is obviously alleviated, and the cognitive level of AD mice is improved. The nasal delivery PF4 mRNA delivery system provided by the invention can be applied to preparation of drugs for treating neurodegenerative diseases, and preferably can be applied to preparation of drugs for treating Alzheimer's disease.

The present disclosure provides a method and a device for diagnosing dementia of a patient on the basis of an olfactory bulb electrical signal. The method according to an embodiment of the present disclosure comprises the steps of: obtaining an electrical signal for an olfactory bulb of a patient; removing an artifact from the obtained electrical signal; obtaining a feature map corresponding to the electrical signal from which the artifact has been removed; and diagnosing dementia of the patient on the basis of the obtained feature map.

The present invention relates to an electromagnetic wave-based olfactory ability treatment method, a user olfactory ability activation device therefor, a control method thereof, and a method for providing information on activation of the olfactory ability of a user. The electromagnetic wave-based olfactory ability treatment method and the user olfactory ability activation device therefor according to the present invention can use electromagnetic waves to stimulate user's olfactory nerves and thereby directly activate the user's olfactory ability through non-invasive stimulation without contact with the user's body, and can achieve consistent therapeutic effects, enables user-customized treatment, and can precisely stimulate specific areas such as the olfactory bulb. In addition, the method and device can not only assess a user's olfactory ability and adjust the pattern and intensity of the electromagnetic waves emitted to the user to provide optimal olfactory ability activation stimulation according to the user, but can also measure changes in the user's electroencephalogram signals due to electromagnetic wave stimulation and provide information on the user's olfactory ability, and thus can be utilized to alleviate, prevent, or treat various diseases, disorders, and conditions related to the olfactory sense.

The invention relates to the technical field of organoid chips, in particular to establishment and application of an olfactory bionic chip model based on an organoid technology. The invention provides an olfactory biochip model construction method, an olfactory biochip model and application thereof, and aims to solve the problems of poor olfactory epithelial layer simulation and insufficient olfactory bulb cell repeatability of a current model and better simulate an olfactory epithelial layer-olfactory bulb layer three-dimensional tissue structure. The olfactory biochip model can realize olfactory conduction, and can solve the problems that the current model cannot receive an odor signal, the survival time of static culture cells is short, and the olfactory signal conduction cannot be visualized.